1[1]Feldman EL.Oxidative stress and diabetic neuropathy:a new understanding of an old problem[J].J Clin Invest,2003,111 (4):431-433.
2[2]Greene DA,Sima AAF,Stevens MJ,et al.Alodose reductase inhibitors:an approach to the treatment of diabetic nerve damage[J].Diabetes Metab Rev,1993,9 (3):189-217.
3[4]Kanamau K,Waga S,Kuga Y,et al.Transcranial Doppler Pattern after intracarotid Papaverine and prostaglandin E1 incorporated inlipid microsphere in patients with vasospasm[J].Neurol Med Chir (Tokyo),1998,38 Suppl:152.
4[5]Ziegler D,Nowak H,Kempler P,et al.Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid:a meta-analysis[J].Diabet Med,2004,21(2):114-121.
6Brownlee M. The pathobiology of diabetic complications: a unifying mechanism[J]. Diabetes, 2005, 54(6): 1615-1625.
7Leibowitz G, Bachar E, Shaked M, et al. Glucose regulation ot β -cell stress in type 2 diabetes[J]. Diabetes Obes Metab, 2010, 12 (Suppl 2): 66-75.
8Asnat BD, Nava B. Proposed mechanisms for the induction of insulin resistance by oxidative stress[J]. Antioxid Redox Signal, 2005, 7(11/12): 1553-1567.
9Ceriello A, Ihnat MA.'Glycaemic variability': a new therapeutic challenge in diabetes and the critical care setting[J]. Diabet Med, 2010, Aug;27(8): 862-867.
10Fridlyand LE, Philipson LH. Reactive species and early manifestation of insulin resistance in type 2 diabetes[J]. Diabetes Obes Metab, 2006, 8: 136-145.
